Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for $10.50 per share in cash, a deal valued at approximately $1 billion, plus a contingent value right (CVR) of up to $3 per share tied to the progress of VERVE-102, potentially increasing the total deal value to $1.3 billion; the acquisition grants Lilly access to Verve's gene therapy pipeline targeting heart diseases, including VERVE-102, which has shown promising early-stage results in reducing cholesterol levels, and VERV shares rallied 76% in pre-market trading following the announcement.

Analysis

Eli Lilly (LLY) has entered into a definitive agreement to acquire Verve Therapeutics (VERV) for $10.50 per share in cash, totaling approximately $1 billion, supplemented by a non-tradable contingent value right (CVR) of up to $3 per share, bringing the potential deal value to $1.3 billion. This CVR is tied to the dosing of the first patient with VERVE-102 in a late-stage study within ten years. The acquisition provides LLY with Verve's gene therapy pipeline targeting heart diseases, notably VERVE-102, an in vivo gene-editing therapy for atherosclerotic cardiovascular disease (ASCVD) which demonstrated encouraging early-stage results in April, showing dose-dependent reductions in blood PCSK9 protein and LDL-C levels, and has received FDA Fast Track designation. This move builds upon an existing partnership where LLY held opt-in rights for VERVE-102. Verve is also developing VERVE-201, with an update anticipated by year-end. Following the announcement, VERV shares surged 76% in pre-market trading, reflecting a significant premium; year-to-date, VERV stock had already gained 9%, outperforming the industry's 2% growth. The transaction, supported by Verve insiders holding nearly 18% of outstanding stock, is expected to close in the third quarter, pending regulatory approvals. This acquisition occurs as LLY, buoyed by the success of its GLP-1 drugs Mounjaro and Zepbound and a market capitalization exceeding $700 billion, actively expands its pipeline, contrasting with peers like Sanofi (SNY) and Bristol Myers (BMY) who face investor pressure for strategic deals.

Key Decisions for Investors

• Verve Therapeutics shareholders should consider the $10.50 per share cash offer plus the potential $3 CVR, noting the substantial pre-market share price increase largely reflects the immediate cash value of the deal.
• Eli Lilly investors can view this acquisition as a strategic expansion into the gene therapy space for cardiovascular diseases, leveraging its strong financial position to acquire promising assets like VERVE-102; progress on VERVE-102 towards late-stage trials will be key for realizing the CVR's full value and validating the acquisition's long-term potential.
• Investors should monitor the biotech sector for further M&A activity, as this deal highlights continued interest from large pharmaceutical companies in acquiring innovative early-to-mid-stage assets, particularly those with positive clinical data and regulatory support like FDA Fast Track designation.